เกี่ยวกับตอนนี้
When you hear the word “aggressive,” it can feel overwhelming, but in diffuse large B-cell lymphoma (DLBCL), it can also point to something encouraging – a potential cure.
In this episode, we speak with Dr. Jonathon Cohen, of Winship Cancer Institute in Atlanta, GA, about what a DLBCL diagnosis really means, from how this common type of non-Hodgkin lymphoma is identified to current treatment options and emerging therapies. We explain what patients and families need to know about side effects. We also look at new treatments, including CAR T-cell therapy and bispecific antibodies, and the importance of open communication with your care team.
CLICK HERE to participate in our episode survey.Mentioned on this episode:
- Diffuse large B-cell lymphoma
- CAR T-cell therapy
- Stem cell transplantation
- Bispecific antibodies (immunotherapy fact sheet)
- Clinical Trial Support Center
Additional Blood Cancer United Support Resources:
- Information Specialists
- Young Adult Resources
- Young Adult Online Chat
- Financial support
- Free Nutrition Consultations
- Free telephone/web patient programs
- SHARE web series
- Online videos
- Free booklets
- Patient Community
- Support groups
- Caregiver support
- Caregiver Workbook
- Survivorship Workbook
- Advocacy and Public Policy
- Mental Health Resources
Episode supported by Genmab US, Inc.
The post Diffuse Large B-Cell Lymphoma (DLBCL): Breaking Down an Aggressive Lymphoma first appeared on The Bloodline with Blood Cancer United Podcast.
